XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
January 03, 2024 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Welcomes New Member to the Board of Directors
January 02, 2024 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces US ATM Offering
November 30, 2023 07:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 30, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Meets Nasdaq Continued Listing Requirements
November 29, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Clarifies Timing for Share Consolidation
November 10, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Share Consolidation
November 08, 2023 17:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 08, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
November 02, 2023 07:00 ET
|
XORTX Therapeutics Inc.
● Preclinical Findings Help Clarify and Reinforce the Role of Uric Acid in the Pathogenesis of Polycystic Kidney Disease and the Potential of XORTX’s Proprietary Formulation of Oxypurinol as...
XORTX Announces Results of Special Meeting of Shareholders
October 27, 2023 17:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 27, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
October 25, 2023 17:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Rescheduling of Special Meeting of Shareholders
October 25, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...